好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Co-Morbid Seizures in Frontotemporal Dementia: What Do They Tell Us?
Aging, Dementia, and Behavioral Neurology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
3-017

This retrospective, single-center study investigated the risk factors, characteristics, and outcomes of seizures in frontotemporal dementia(FTD+SZ) compared to FTD without seizures(FTD-SZ).

 Seizures are associated with accelerated cognitive decline in dementia. Comorbid seizures are common in FTD, yet understudied. 

All patients coming to our hospital with clinically-diagnosed FTD from 2011-2024 were classified into 1)FTD+SZ) and2)FTD-SZ. FTD+SZ was defined as having any seizure observed. FTD was classified into behavioral-variant FTD(bvFTD),sematic-variant-primary-progressive aphasia(svPPA) or non-fluent-primary-progressive-aphasia(nfPPA).  Data on baseline demographics, seizure characteristics, and outcomes were obtained from EMR. Data were analyzed using Pearson’s Chi-squared test, fisher exact test, or t-tests.

Of 326 FTD patients(average age of dementia onset=64+9years, 46% female) who met the inclusion criteria, 10%(N=33) had seizures. The average age of seizure-onset was 63+13years in FTD+SZ. Traumatic brain injury(TBI) was the only significant risk factor for seizures in FTD(FTD+SZ=8 (24%) vs FTD-SZ=18(6%), p<0.001). All other characteristics were comparable among the groups. bvFTD was more prevalent in FTD+SZ compared to FTD-SZ(58% vs 50%). Of these, 16(48%) had epilepsy, seven (21%) had one-time unprovoked seizures, and seven(21%) had provoked seizures due to secondary causes.   Fourteen(42%) patients had focal-epilepsy, 11(33%) had generalized-epilepsy, and epilepsy type was unknown for the remaining 8(24%) patients.  Five(36 %) patients with focal epilepsy were diagnosed with temporal-lobe-epilepsy. For patients with focal epilepsy, 12(86%) patients had focal seizures with impaired awareness, 3(21%) of whom experienced secondary generalization. Twenty-five(76%) achieved control on ASMs and seizures self-resolved in the remaining 8(24%)FTD+SZ. 

Around 10% of FTD patients experience seizures. TBI was the most frequent risk factor associated with seizures in FTD. Seizures are more commonly associated with the behavioral variant of FTD. In FTD, focal epilepsy is most common, with temporal lobe epilepsy being the most prevalent subtype. The majority achieved seizure control. While not uncommon, seizures in FTD have a favorable outcome.

Authors/Disclosures
Syeda Amrah Hashmi, MBBS
PRESENTER
Dr. Hashmi has nothing to disclose.
Jaideep Kapur, MD, PhD (UVA Neurology) The institution of Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Marinus. Dr. Kapur has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Robert Wood Johnson Foundation . Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Kapur has received research support from NIH. Dr. Kapur has received intellectual property interests from a discovery or technology relating to health care. Dr. Kapur has a non-compensated relationship as a Chair, Board North America with International League against Epilepsy that is relevant to AAN interests or activities. Dr. Kapur has a non-compensated relationship as a Board of Directors with American Epilepsy Society that is relevant to AAN interests or activities.
Mark S. Quigg, MD (UVA Neurology) Dr. Quigg has received personal compensation for serving as an employee of Natus. Dr. Quigg has received personal compensation for serving as an employee of Neurocrine. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Finnigen and Harrison. Dr. Quigg has received research support from NIH. Dr. Quigg has received publishing royalties from a publication relating to health care.
Anelyssa Cysne Frota D' Abreu, MD, PhD, MPH, FAAN (Corewell Health Outpatient Neurology) The institution of Dr. Cysne Frota D' Abreu has received research support from U.S. NIH Institute on Aging. The institution of Dr. Cysne Frota D' Abreu has received research support from Biogen. The institution of Dr. Cysne Frota D' Abreu has received research support from American College Of Radiology. The institution of Dr. Cysne Frota D' Abreu has received research support from COGNITION THERAPEUTICS, INC.. The institution of Dr. Cysne Frota D' Abreu has received research support from Eli Lilly. The institution of Dr. Cysne Frota D' Abreu has received research support from Jansen. Dr. Cysne Frota D' Abreu has received personal compensation in the range of $10,000-$49,999 for serving as a Lecturer with Pri_med.
Carol A. Manning, PhD The institution of Dr. Manning has received research support from Department of Defense.
Ifrah Zawar, MD (University of virginia) The institution of Dr. Zawar has received research support from Alzheimer's association. The institution of Dr. Zawar has received research support from American epilepsy society . The institution of Dr. Zawar has received research support from NIH. The institution of Dr. Zawar has received research support from University of Virginia.